Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248040 · ClinicalTrials.gov registry record · Phase 2
Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation
A Phase 2 study, sponsored by Dompé Farmaceutici S.p.A.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00248040 is a Phase 2 study that has completed, run by Dompé Farmaceutici S.p.A. The registered enrollment target is 80 participants.
The verdict
NCT00248040, a Phase 2 study, has completed, sponsored by Dompé Farmaceutici S.p.A.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Reparixin is a novel, specific inhibitor of CXCL8. This study is configured to explore the safety and efficacy of reparixin in preventing the delayed graft function (DGF) after kidney transplantation.
Interventions
- DRUG Reparixin continuous infusion
- DRUG reparixin intermittent infusion
- OTHER placebo infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00248040
The ClinicalTrials.gov registry entry for NCT00248040 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dompé Farmaceutici S.p.A, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Reparixin continuous infusion is the first listed.
NCT00248040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00248040 about?
NCT00248040 is a clinical study titled "Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation". The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Reparixin is a novel, specific inhibitor of CXCL8. This study is configured to explore the safety and efficacy of reparixin i...
What is the current status of trial NCT00248040?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2005-10. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00248040?
The interventions under investigation include: Reparixin continuous infusion (DRUG), reparixin intermittent infusion (DRUG), placebo infusion (OTHER).
Who is sponsoring clinical trial NCT00248040?
This trial is sponsored by Dompé Farmaceutici S.p.A, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.